Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at American Association for Cancer Research Annual Meeting 2026
- Written by PR Newswire
Data Demonstrate Activity in HER2-Low and ADC-Resistant Tumor Models, Supporting Advancement Toward IND
SHANGHAI and SUZHOU, China, April 14, 2026 /PRNewswire/ -- Phrontline Biopharma today announced the presentation of preclinical data for TJ106, a next-generation biparatopic HER2-targeting antibody-drug conjugate (ADC) with a dual-payload...
